![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | C07D 235/14 | (2006.01) |
A61P 35/02 | (2006.01) | ||
A61K 31/4184 | (2006.01) |
(11) | Number of the document | 3452035 |
(13) | Kind of document | T |
(96) | European patent application number | 17793075.7 |
Date of filing the European patent application | 2017-05-01 | |
(97) | Date of publication of the European application | 2019-03-13 |
(45) | Date of publication and mention of the grant of the patent | 2021-07-07 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2017/030414 |
Date | 2017-05-01 |
(87) | Number | WO 2017/192451 |
Date | 2017-11-09 |
(30) | Number | Date | Country code |
201662330673 P | 2016-05-02 | US |
(72) |
DUNCAN, David , US
|
(73) |
MEI Pharma, Inc. ,
11455 El Camino Real, Suite 250, San Diego, CA 92130,
US
|
(54) | POLYMORPHIC FORMS OF 3-[2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL]-N-HYDROXY-ACRYLAMIDE AND USES THEREOF |
POLYMORPHIC FORMS OF 3-[2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL]-N-HYDROXY-ACRYLAMIDE AND USES THEREOF |